Partnerships
Advancing Programs Through Strategic Collaboration
Innovex Discovery is seeking partnerships that can accelerate development of PSA-activated prodrugs, expand payload opportunities, and support efficient translation toward the clinic.
Partnership Opportunities
⬡
Program Co-Development
Collaborate to advance the lead PSA-activated doxorubicin program through shared expertise in prodrug pharmacology, preclinical development, or translational strategy.
◈
Payload and Platform Expansion
Explore PSA-activated applications for additional cytotoxic payloads – leveraging the platform’s selectivity and design principles to extend into new therapeutic candidates.
◇
Licensing and Strategic Transactions
Evaluate regional, global, or asset-specific licensing structures aligned with your organization’s development priorities and commercial strategy.
What Innovex Brings
Differentiated Biology
Differentiated Biology
A PSA-activated approach designed for localized drug release in prostate tumors – grounded in the biology of PSA overexpression and supported by patents and publications in the field.
Integrated Development
Integrated Development Strategy
Coordinated medicinal chemistry, DMPK, translational science, and candidate-selection leadership – keeping scientific decision-making integrated from hypothesis through data.
Flexible Collaboration
Flexible Collaboration
Partnership structures tailored to program stage, payload opportunity, and strategic goals – whether that means co-development, licensing, or a defined research collaboration.
How We Partner
01
Explore Fit
Align on scientific rationale, strategic objectives, and program scope – ensuring a shared understanding of what each partner brings and what success looks like.
02
Define the Collaboration
Establish roles, workstreams, decision points, and transaction structure – with clear governance and milestones that keep the collaboration on track.
03
Advance the Program
Execute against agreed milestones with transparent scientific and development oversight – maintaining alignment as data emerge and priorities evolve.
Let’s Explore the Right Collaboration.
We welcome conversations with biotechnology and pharmaceutical companies, investors, research organizations, and development partners interested in PSA-activated prodrugs and tumor-selective oncology.
